• $55.1M
    Market Cap
  • 291.78%
    1-Year Change
  • Medical Instruments & Supplies
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 44
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Trump Sparks A 2025 IPO Boom: 5 New Stocks Have Rallied Over 400%

The U.S. IPO market is experiencing a strong revival in 2025, with 163 companies going public and raising $31 billion, driven by a favorable business climate under President Trump's second term and increased investor risk appetite.

10/07/2025, 4:09 PM • Benzinga

Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System

Anbio Biotechnology launched a Chikungunya IgM/IgG Rapid Test and an AP-100 Ultra-Fast PCR system to support rapid diagnostic testing for infectious diseases, enabling quick detection of pathogens in both centralized and decentralized healthcare settings.

08/08/2025, 9:05 PM • GlobeNewswire

Peers

Statistics

More
Day Range
$31.05
$33.30
$32.12
1-Year Range
$8.20
$52.10
$32.12
Latest Close$32.12
Change
+$1.95 (+6.07%)
Volume13,504
Market Cap$55.1M
Shares Outstanding1.6M
P/E (TTM)234.08
Diluted EPS (TTM)$0.15
Enterprise Value$47.3M

Information as of 06/02/2026

Company Profile

$55.1M
Market Cap
$6.4M
Net Income
Sector: Healthcare
Industry: Medical Instruments & Supplies
Friedrich-Ebert-Anlage 35-37, Frankfurt am Main, Germany, 60327
49 698 7003 9170

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.

Key Executives

  • Michael Lau
  • Chris Tian
  • Suki Song

Current Ownership Distribution

  • Other43.8M (99.89%)
  • Institutions50,226 (0.11%)
  • Mutual Funds0 (0.00%)
  • Insiders0 (0.00%)